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Abstract: The historical approach of diagnosing cancer types based entirely on anatomic origin and
histologic features, and the “one-size-fit-all” therapeutic approach, are inadequate in modern cancer
treatment. From decades of research we now know that cancer is a highly heterogeneous disease driven by
complex genetic or epigenetic alterations. The advent of various high throughput molecular tools has now
enabled us to view and sub-classify each cancer type based on their distinct molecular features, in addition
to histologic classification, with the promise of individualized treatment strategies tailored towards each
specific subtype to improve patient outcomes. In this review, we have made an effort to systematically review
the most up-to-date, leading literature in molecular analysis and/or subtyping of major gastrointestinal
cancers. These include esophageal squamous cell carcinoma (ESCC), gastric cancer (GC) adenocarcinoma,
pancreatic ductal adenocarcinoma (PDAC), hepatocellular carcinoma (HCC), gallbladder cancer (GBC), and
colorectal cancer (CRC). For each cancer type we summarized the global mutational landscape, subgroup
classification based on genomics, epigenetics, gene expression and/or proteomic analysis, and their salient
clinicopathological features. We have highlighted the actionable mutations or mutational pathways that
could help guide targeted therapies in the future.
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genomics; epigenetics
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Introduction
Accurate classification is a requisite in the diagnosis,
treatment and prognostication of cancer. Historically
cancers have been classified according to the anatomic
site of origin and histologic appearance, with the broad
assumption that cancers from the same origin share
common pathogenic processes. However, morphologically
similar cancers can have widely variable clinical course and
response to the same treatment, indicating fundamental
differences in the pathogenic processes that drive each
cancer. As cancer arises from distinct alterations in genetic
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and epigenetic events that culminate in transformed cellular
behavior, being able to identify the crucial events that
drive each cancer should ideally help optimize treatment
decisions and improve patient outcomes, which are the
principal goals of “personalized oncology”. The emergence
of high throughput molecular tools in the past two decades
including mRNA microarray, next generation DNA and
RNA sequencing, methylation array and various proteomic
tools have brought us closer towards these goals. We are
now able to comprehensively visualize the salient genomic
characteristics, gene expression profiles and proteomic
information of each cancer case and start categorizing them
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into “molecular” subtypes, which theoretically should better
reflect the biology and behavior of each cancer. In fact,
the past decade has seen an explosion of cancer genomic
and transcriptomic analyses, and tremendous efforts to
sub-categorize each cancer type based on these molecular
features. Though still at its infancy, this new way of cancer
classification holds promise to allow more refined clinical
trial designs, more optimal patient allocation to targeted
therapeutics, and prognostication, which will ultimately
help both the patients and treating physicians.
In this article, we have reviewed the most recent
landmark literature in molecular analysis and/or subtyping
of major gastrointestinal cancers. These include esophageal
squamous cell carcinoma (ESCC), gastric adenocarcinoma,
pancreatic ductal adenocarcinoma (PDAC), hepatocellular
carcinoma (HCC), gallbladder cancer (GBC) and colorectal
cancer (CRC). More attention will be paid towards gastric,
pancreatic ductal and colorectal adenocarcinoma since these
cancers are more common and best studied.
Overview of molecular landscape and
classifications of GI cancers
Gastric cancer (GC)
GC, which consists predominantly of adenocarcinoma, is
the fifth most common cancer globally, and third leading
cause of cancer deaths in 2012 (1). The first and most
comprehensive molecular characterization of gastric
adenocarcinoma was reported by the Cancer Genome
Atlas Research Network (2). In this study, 295 treatment
naïve primary gastric adenocarcinoma samples were
characterized using six different molecular platforms
including array-based somatic copy number analysis, wholeexome sequencing (WES), array-based DNA methylation
profiling, messenger RNA sequencing, microRNA (miRNA)
sequencing and reverse-phase protein array. Integrated
analysis of data from the platforms identified four distinct
subtypes. Notably, no survival or racial differences were
found among patients from each subgroup.
(I) Epstein-Barr virus-infected (EBV, 9% samples):
signified by high EBV burden, extensive DNA
promoter hypermethylation (including universal
CDKN2A promoter hypermethylation), frequent
PIK3CA (80%), ARID1A (55%) and BCOR (23%)
mutations, amplification of 9p24.1 locus (15%)
containing genes encoding JAK2, PD-L1 and PD-L2.
These data suggest potential therapeutic role for PI3K
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inhibitors, JAK2 inhibitors and immune checkpoint
antagonists in this subgroup. EBV-GC were mostly
located in the gastric fundus or body (62%) and more
frequently found in male patients (81%).
(II) Microsatellite instability (MSI, 22% samples): signified
by hypermutated genome and DNA hypermethylation
(including MLH1 promoter hypermethylation).
Mutations in PIK3CA, EGFR, ERBB2, and ERBB3
were seen. MSI-GC tumors were diagnosed at an
older age (median age 72 years), with a slightly higher
prevalence in female patients (56%).
(III) Genomically stable (GS, 20% samples): signified by
tumors with low somatic copy-number aberrations.
GS-GC is enriched for CDH1 mutations (37%),
which underlie hereditary diffuse GC syndrome, and
either RHOA mutations or CLDN18-ARHGAP
rearrangements (30%, mutually exclusive) which
may enhance invasiveness and disrupt intercellular
cohesion and contribute to the diffuse histology found
in 73% of this subtype. GS-GC was diagnosed more
frequently in younger patients (median age 59 years).
(IV) Chromosomal instability (CIN, 50% samples):
signified by high somatic copy-number aberrations.
High frequency of TP53 mutations (73%), genomic
amplifications of genes in the receptor tyrosine
kinase—Ras pathway including VEGFA, EGFR
(10%), ERBB2 (24%), ERBB3 (8%), c-Met (8%),
amplification of genes encoding cell cycle mediators,
such as CCNE1, CCND1 and CDK6. These
findings suggest potential use of many targeted
agents towards this subtype. CIN-GC is found more
frequently in the gastroesophageal junction/cardia
(65%) and exhibits an intestinal histology.
Another major study was from the Asian Cancer
Research Group (ACRG) (3,4). In this study, 300 GC were
profiled using gene expression, genome-wide copy number
microarray and targeted sequencing, yielding four distinct
molecular subtypes. Importantly, each molecular subtype is
associated with distinct prognosis.
(I) MSI-high (22.7% or 68/300 cases): this subtype
occurred frequently in the antrum (75%), with
>60% of cases exhibiting the intestinal subtype, and
more than half of the cases diagnosed at early stages
(I/II). This subtype had the best prognosis, and
was associated with the presence of hypermutation,
in addition to mutations in genes such as KRAS
(23.3%), the PI3K-PTEN-mTOR pathway (42%),
ARID1A (44.2%) and ALK (16.3%).
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(II)

Microsatellite stable/epithelial-mesenchymal
transition (MSS/EMT, 15.3% or 46/300 samples):
this subgroup was found to occur at a significantly
younger age with the majority diagnosed with diffusetype histology and at advanced stages (III/IV). This
subtype had the worst overall prognosis and a
higher chance of recurrence compared to the MSI
subgroup.
(III) Microsatellite stable/epithelial/TP53 intact (MSS/
epithelial/TP53+, 26.3% or 79/300 samples): EBV
infection occurred predominantly in this subgroup
compared to other groups. This subtype had the
second-best prognosis followed by MSI.
(IV) Microsatellite stable/epithelial/TP53 loss (MSS/
epithelial/TP53 −, 35.7% or 107/300 samples):
tumors falling under this subgroup had a less
favorable prognosis compared to MSI and MSS/
epithelial/TP53+. As expected, this subgroup had
the highest rate of TP53 mutations (60%).
The ACRG work (3,4) supplemented the TCGA
analysis (2) by introducing TP53 activity and EMT in
the classification. The two studies had similarities and
differences. The MSI tumors were found in both datasets,
and there was some overlap between GS, EBV+, and CIN
subgroups defined by TCGA and MSS/EMT, MSS/TP53+,
and MSS/TP53− of the ACRG respectively. However, several
differences in terms of molecular mechanisms, driver genes
and prognosis were observed between the two cohorts.
PDAC
PDAC is the fourth leading cause of cancer death in the United
States and is projected to be the second by 2020 (5). The
overall 5-year survival of PDAC is 7% (6). The extremely
poor prognosis of PDAC highlights the urgent need to
understand and target the molecular aberrations that
drive this disease. Collisson et al. (7) first classified microdissected pancreatic adenocarcinoma samples using gene
expression analysis into three subtypes:
(I) Classical subtype: this subtype is characterized
by high expression of adhesion-associated and
epithelial genes, overexpression of GATA-binding
protein 6 (GATA6), higher KRAS mRNA level and
dependence on KRAS, more sensitivity to erlotinib
and best survival outcomes.
(II) Quasimesenchymal (QM) subtype: this subtype is
characterized by high expression of mesenchymeassociated genes, more sensitivity to gemcitabine and
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has the worst survival outcomes of all three subtypes.
(III) Exocrine-like subtype: as the name implies, this
subtype has the highest presence of tumor cellderived digestive enzyme genes.
In a more elaborate study, Waddell et al. performed
whole-genome sequencing (WGS) and copy-number
variation (CNV) analysis of 100 PDACs. Based on structural
variations, four subtypes were proposed (8).
(I) Stable subtype (subtype 1): accounts for 20% of
samples, contains <50% structural variation events.
Point mutations of KRAS, SMAD4, and telomere
length in this subtype was not different compared
to other subtypes.
(II) Locally rearranged subtype (subtype 2): accounts
for 30% of all samples. About 1/3 of these samples
showed focal regions of gain/amplifications, leading
to copy number gain of genes including KRAS, SOX9,
GATA6, and at a lower prevalence (1–2% of patients)
of targetable mutations such as ERBB2, MET, CDK6,
PIK3CA and PIK3R3. The remaining 2/3 of this
subtype contained complex genomic events.
(III) Scattered subtype (subtype 3): 36% of samples
belonged to this subtype with an intermediate
range of non-random chromosomal alterations and
<200 structural variation events.
(IV) Unstable subtype (subtype 4): accounts for 14% of
samples, characterized by a large number (>200,
maximum 558) of structural variations suggestive
of defects in DNA stability. This subtype showed
strong relationship with mutations in BRCA
pathway genes (BRCA1, BRCA2 and PALB2).
Patients under the unstable subtype with a high
BRCA germline mutational burden were found to
be better responders to platinum based therapy.
The same group later performed a larger scale, more
comprehensive analysis including whole genome sequencing,
copy number variation and gene expression analyses,
histopathologic and clinical correlation, on 456 PDAC
samples (9). In this study, 32 significantly mutated genes
assembled in 10 molecular pathways were identified. These
include:
 Activating mutations of KRAS in 92%;
 Disruption of G1/S checkpoint mechanism in 78%
(TP53, CDKN2A, and TP53BP2);
 TGF-B sign alin g in 47% (SMAD3, SMAD4,
TGFBR1, TGFBR2, ACVR1B and ACVR2A);
 Histone modification in 24% (KDM6A, SETD2,
ASCOM complex members MLL2 and MLL3);
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 The SW1/SNF complex in 14% (ARID1A, PBRM1
and SMARCA4);
 The BRCA pathway 5% germline and 12% somatic
(BRCA1, BRCA2, ATM, PALB2);
 WNT signaling defects through RNF43 mutation in 5%;
 RNA processing genes in 16% (SF3B1, U2AF1, and
RBM10).
In addition, transcriptome analysis of 96 PDAC tumors
with ≥40% epithelial cellularity revealed four different
subtypes (9):
(I) Squamous subtype: associated with mutations in
TP53, KDM6A, activated α6β1, α6σ4, EGF signaling,
hypermethylation and subsequent downregulation
of genes determining pancreatic endodermal cell
fate. In general, gene sets involved in inflammation,
hypoxia response, metabolic reprogramming, TGF-B
signaling, MYC pathway activation, autophagy and
upregulated expression of TP63(delta)N characterize
this subtype. This subtype is associated with the worst
survival outcomes.
(II) Pancreatic progenitor subtype: characterized by
activated transcription factors such as PDX-1,
that regulate differentiation from endoderm to
pancreatic lineage, inactivating mutations of
TGFBR2, and gene programs involved in fatty
acid oxidation, steroid hormone biosynthesis, drug
metabolism, and O-linked glycosylation of mucins.
(III) Aberrantly differentiated endocrine exocrine
(ADEX) subtype: defined by activated transcription
factors that regulate later stages of pancreatic
development and differentiation, including NR5A2,
MIST1, RBPJL, INS, NEUROD1, MAFA.
(IV) Immunogenic subtype: this subtype shares many
of the characteristics of the progenitor class, but
is associated with significant immune infiltrate.
Immune gene sets with a role in B- and T-cell
signaling pathways, and antigen presentation
delineate this subtype. Particularly upregulation of
CTLA4 and PD1 acquired tumor response pathways
in this subtype have therapeutic implications.
Three of the subtypes introduced by Bailey et al. directly
overlap with Collisson subtypes presented earlier. QM-PDAC
subtype in the Collisson study was renamed to squamous
to better elucidate the common features of this specific
type in PDAC with squamous type seen in other organs
such as breast, bladder, lung, and head and neck; classical
was renamed to pancreatic progenitor to better explain
the presence of gene sets involved in early pancreas
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development in this subtype; and exocrine like was changed
to ADEX to further include the endocrine differentiation in
addition to exocrine differentiation.
Given the fact that genomic analysis of PDAC is
frequently hampered by the sparse tumor cellularity and
the presence of abundant stroma intermixed with normal
endocrine and exocrine cells, Moffitt et al. performed virtual
microdissection of 145 primary and 61 metastatic PDAC
samples to overcome this challenge (10). In their study, they
identified tumor-specific and stroma-specific subtypes with
prognostic and biological relevance. Their study identified
two stroma-specific subtypes:
(I) Activated stromal subtype: patients belonging to
this subtype had a worse median survival time
of 15 months and 1-year survival rate of 60%
vs. 24 months and 80% when compared to the
normal stromal subtype group. This subtype
was characterized by a more diverse set of genes
associated with macrophages, such as integrin
ITGAM and chemokine ligands CCL13 and
CCL18, WNT family members (WNT2 and
WNT5A), MMP9 and MMP11, and FAP which
has been associated with poor outcomes (11).
(II) Normal stromal subtype: this subtype was
characterized by high expression of known
markers for pancreatic stellate cells (ACTA2,
VIM, and DES, encoding for actin, vimentin and
desmopressin respectively).
Moffitt et al. also identified two separate tumor-specific
subtypes, independent of normal and stromal factors:
(I) Classical tumor subtype: there was a strong overlap
between genes of this subtype and the classical
subtype defined by Collisson et al. earlier in this
section (7). In concert with Collisson et al. results,
the classical subtype in this study was also enriched
for genes associated with GATA6 overexpression.
In addition, SMAD4 expression was found to be
consistently higher in this subtype consistent with
the observation that loss of SMAD4 confers a more
aggressive tumor phenotype.
(II) Basal-like tumor subtype: patients in this tumor
subtype had a worse median survival time of
11 months and 1-year survival rate of 44%
compared to 19 months and 70% of that of classical
tumor subtype. Despite worse prognosis, patients
belonging to this subtype revealed a strong trend
toward response to adjuvant therapy. Manually
curated RNA-seq data showed that KRAS
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mutation encoding p.Gly12Asp was significantly
overrepresented in this subtype.
Basal like and classical tumors were found in both the
normal and activated stromal subtype. As expected, tumors
from the classical subtype with normal stromal subtype had
the best prognosis, and tumors from the basal-like subtype
with activated stromal subtype had the worst prognosis (10).
CRC
CRC, or adenocarcinoma, is a disease with extensive
intraclonal heterogeneity resulting in various outcomes and
drug responses (12). However, molecular subtyping reported
by different groups, based mainly on gene expression analysis,
showed low consistencies, thereby posing great challenges
in clinical translation (13-20). To reconcile these differences,
the international CRC subtyping consortium (CRCSC) was
formed to re-analyze 18 published datasets (N=4,151) (21).
Four consensus molecular subtypes (CMS) were identified:
(I) CMS1; MSI immune (14%): characterized by
hypermutated genome with few somatic copy
number aberrations (SCNAs); encompasses the
majority of MSI tumors and exhibits proteomic
features suggestive of defective DNA mismatch
repair; high frequency of BRAF mutations;
increased expression of genes associated with
a diffuse immune infiltrate along with strong
activation of immune evasion pathways. These
features make this subtype an appropriate target
for immune checkpoint inhibition. Clinically,
these tumors were dominant in female patients,
mostly presenting as right-sided lesions with
higher histopathological grade. In terms of clinical
outcomes, these tumors proved to have a very poor
survival rate with every recurrence.
(II) CMS2; canonical (37%): characterized by high
prevalence of SCNAs, and amplifications of
transcription factor HNF4A. Gene expression
profiling showed epithelial differentiation and
strong upregulation of WNT and MYC downstream
targets, both of which have been indicated in CRC
carcinogenesis. These tumors mostly presented as
left-sided lesions.
(III) CMS3 (13%); metabolic: this subtype had distinct
genomic and epigenomic features when compared
with other chromosomal instability (CIN) subtypes
(CMS2-4). In brief these tumors were found to have
(i) consistently fewer SCNAs, (ii) hypermutation
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in 30% of samples, an overlap feature with CMS1
tumors, (iii) a higher prevalence of CpG island
methylator phenotype (CIMP)-low clusters with
intermediate levels of genome hypermethylation. A
high frequency of KRAS mutations were observed
in this subtype in addition to other genes involved
in metabolism.
(IV) CMS4; mesenchymal (23%): gene expression
profiling of this subtype revealed clear upregulation
of genes involved in epithelial-to-mesenchymal
transition (EMT), activation of transforming
growth factor-β (TGF-β), angiogenesis, matrix
remodeling pathways and complement associated
inflammatory response. Clinically, these tumors
were mostly diagnosed at more advanced stages (III/
IV). In terms of clinical outcomes, these tumors
tended to have worse overall survival and worse
relapse-free survival.
ESCC
Esophageal cancer is the 8th most common cancer globally.
ESCC is the most common histological type worldwide (1,22).
The mutational landscape of ESCC was investigated
by Gao et al. through WES of 113 tumor-normal paired
samples of treatment-naïve ESCC (23). The median number
of mutations was found to be 2.9 non-silent mutations
per megabase, far fewer than that of smoking-related
bronchogenic carcinomas and UV-mediated melanomas.
In addition, SCNA were found in 72% of cases. Genes
responsible for regulating cell cycle, apoptosis, and DNA
damage were found to be mutated in 99% of cases [TP53
(93%), CCND1 (33%), CDKN2A (20%), NFE2L2 (10%),
and RB1 (9%)]. Histone modifying genes were found to be
mutated in 63% of all ESCC cases [MLL2 (19%), MLL3
(6%), KDM6A (7%), EP300 (10%), and CREBBP (6%)].
The Hippo and NOTCH pathways were also frequently
dysregulated through a number of inactivating mutations
[FAT1-4 (27%), AJUBA (7%), NOTCH1-3 (22%) and
FBXW7 (5%)] (23).
ESCC cases with EP300 mutation had a less favorable
prognostic outcome when controlled for other confounders
such as TNM staging, age, gender, smoking and drinking
history. This mutational analysis found major similarities
between ESCC with squamous cell carcinoma of other
primaries (head and neck and lung squamous cell
carcinomas), but showed considerable differences when
compared to that of esophageal adenocarcinomas (23).
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HCC
HCC is the third cause of cancer related mortality in the
world (22,24). In the past 10 years, considerable efforts
have been made to segregate HCC, primarily based on
gene expression technologies, into different prognostic
groups (25,26). However, several factors underlie the
heterogeneity of HCC. Epidemiologically, the incidence
of HCC varies widely across different geographic regions,
ancestral heritage, and genders. Furthermore, the etiologies
of HCC differ markedly according to ancestry: chronic
hepatitis B is the predominant cause of HCC in East
Asia and Africa, whereas hepatitis C is more common in
Japan and Western countries; Aflatoxin B1 exposure is
a causative environmental factor in Asia and Africa, as
opposed to alcohol consumption in Western countries
(27,28). Therefore, it is reasonable to account for these
differences in genomic analysis and subtyping of HCC.
In a collaborative work between the International Cancer
Genome Consortium (ICGC) and The Cancer Genome
Atlas (TCGA) project, Totoki et al. conducted the first
trans-ancestry HCC genome sequencing in 608 cases of
liver cancer (503 sequenced by Totoki et al., integrated with
105 from TCGA) (29). This cohort contained samples from
patients with diverse ancestral backgrounds: European, USAsian, African-American and Japanese. Among the cohort,
212 patients were HCV positive, 117 HBV positive, and
150 not infected by hepatitis viruses.
The average mutation rate was found to be 2.8
mutations per megabase. In terms of CNAs, about 29% of
the cases showed gross chromosomal loss (average ploidy
3.87, and the average number of CNAs was 11.58). The
following oncogenic pathways held significance in this
analysis:
 TP53-RB pathway. Inactivation of this pathway is a
recurring theme in HCC tumorigenesis. TP53 and
RB1 mutations were observed in 31% and 4.4%
of tumors respectively. Overall 72% of cases had
mutations in component genes of one or both of these
pathways such as CDKN1A and CDKN2A.
 WNT pathway. Activating CTNNB1 mutations and
inactivating mutations of AXIN1 and APC were found to
be signatures of this pathway. Overall 66% of HCC cases
harbor a mutation in one of the WNT pathway genes.
 Chromatin and transcription modulators. Mutations
involved in this pathway include alterations in
NFE2L2, and nucleosome remodelers ARID1A,
ARID2 and BRD7.
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 mTOR-PIK3CA pathway. Recurrent inactivating
mutations in TSC1-TSC2 and activating mutations
of PIK3CA are the signatures of this pathway. Other
modulators such as NF1, PTEN, INPP4B and STK11
were also mutated. In general, 45% of cases had some
kind of alteration in the mTOR-PIK3CA pathway.
 Interestingly, TERT (which encodes telomerase)
promoter mutations were detected in total of
54% of cases, with the highest frequency among
HCV positive patients (121/188; 64%), and lower
frequencies in non-viral and HBV positive cases, 59%
and 37% respectively. TERT promoter mutations
significantly co-occurred with WNT pathway gene
mutations in HCV and non-viral cases suggesting
a permissive oncogenic activity between the two in
these group of patients. These findings suggest that
TERT is a driving mutation with potential therapeutic
targetability. Alterations of ATRX, which allows
telomerase-independent telomere maintenance,
have also been reported. More than 68% of patients
had either mutations in TERT or ATRX as the most
frequent molecular event.
In addition to the abovementioned findings, this study
also found ancestry dependent diversity in HCC mutation
signatures regardless of hepatitis virus status or gender (29).
One signature featured by CTG>CAG mutations
dominated the cases of US-Asian male and female patients,
whereas another signature characterized by AT>AC
mutations was frequently seen in Japanese male cases.
These findings indicate more complicated intra- and interancestry variations and/or environmental exposures.
GBC
GBC is a rare aggressive tumor with median survival
time of less than 1 year (30). To further understand the
somatic mutation spectrum in GBC, Li et al. performed a
combined WES and ultra-deep sequencing of 57 tumornormal pairs of pathologically confirmed cases of GBC (31).
Their sequencing efforts revealed TP53 and KRAS as being
recurrently mutated, with mutation rates of 47.1% and 7.8%
respectively. Interestingly, this study identified recurrent
mutations in ErbB signaling pathway: ERBB1 (also known
as EGFR) 3.9%, ERBB2 9.8%, ERBB3 11.8%, and ERBB4
3.9%. This study showed that overexpression of each
ERBB2 and ERBB3 mutations result in a significant increase
in proliferation in at least one cell line when compared to
the wild type, highlighting the role of ErbB family receptors
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in GBC development and progression.
In addition, Li et al. found that cases harboring one of
the ErbB family signaling pathway mutations have worse
prognostic outcomes in terms of overall survival when
compared to their control counterparts (median of 8 vs.
13 months; P=0.012) (31). These results suggest that
patients with one of ErbB family mutations will potentially
benefit from targeted therapies against these specific
mutations.
Conclusions
In this article, we reviewed different subclassification
systems proposed for each major gastrointestinal cancer
type based on various molecular tools including next
generation sequencing, gene expression analysis, and
application of sophisticated analytic algorithms. Although
these subgroups have deepened our understanding of the
global mutational landscape and signaling aberrations of
each cancer types, they have also posed major challenges
and elicited important questions that need to be further
investigated. For instance:
 How can different sub-classification systems be
reconciled between study groups?
 How does one interpret the significant discrepancies
in results derived from genomic, transcriptomic and
proteomic tools to appropriately guide therapeutic
decision making?
 What is the standardized way of preparing and
analyzing tumor samples in order to allow accurate
sub-classification?
 Virtually all solid cancers are clonally heterogeneous
and constantly evolving especially under the selection
pressure of therapeutics (32). Do cancer subtypes
change throughout the disease course?
 Within each subclass, how can driver and passenger
mutations be further distinguished to inform
treatment decision?
 How could these sophisticated analyses be distilled
down to simple, valid and reproducible assays that can
be applied in patient care in a timely fashion?
 Do tumor specimens derived from different sites
(primary vs. metastatic) share the same molecular
subtype?
Numerous basic and translational research are in progress
to improve our current understanding and fill existing
knowledge gaps in cancer biology. The tremendous quest
in molecular subtyping of gastrointestinal malignancies, as
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is being done in cancers from other anatomic sites, is only
meaningful if it can truly impact patient care. Much work
remains to be done to standardize and streamline sample
processing, data analysis and establishment of algorithms, to
create reproducible and reliable diagnostic tools that can be
used in daily practice. Of equal significance, development
of effective therapeutic agents must follow the rapid pace
of development in molecular diagnostics. Lastly, all these
sophisticated and costly level of work that already are the
basis of personalized oncology must be cost-effective and
affordable to patients. Regardless of all these challenges,
cancer genomics has irreversibly changed our mindset
on cancer classification as many diseases rather than one
disease, and has revolutionized our approach towards
individualizing treatment.
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